

# Plasmid Containing H2 Hemagglutinin (HA) Gene from Influenza A Virus, A/mallard/Netherlands/5/1999 (H2N9)

## Catalog No. NR-28994

This reagent is the tangible property of the U.S. Government.

## Product Description:

The H2 hemagglutinin (HA) gene from influenza A virus, A/mallard/Netherlands/5/1999 (H2N9) (GenBank: [CY064950](#)), was cloned into a modified version of the bidirectional reverse genetics plasmid, pHW2000. NR-28994 lot 70063766 was extracted from a preparation of BEI Resources seed lot 63417486, produced in *Escherichia coli* Stbl2™ cells (Invitrogen™ 10268), in the presence of 100 µg/mL ampicillin and extracted using Plasmid Plus Maxi Kit (QIAGEN® 12963).

**Lot: 70063766**

**Manufacturing Date: 27SEP2023**

| TEST                                                                                        | SPECIFICATIONS                                                                       | RESULTS                                                                             |
|---------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Next-Generation DNA Sequencing</b>                                                       | ~ 4700 base pairs                                                                    | 4641 base pairs <sup>1</sup>                                                        |
| <b>Genotypic Analysis</b><br>Sequencing of H2N9 Hemagglutinin gene insert (1771 base pairs) | ≥ 99% sequence identity to A/mallard/Netherlands/5/1999 (H2N9) (GenBank: CY064950.1) | 100% sequence identity to A/mallard/Netherlands/5/1999 (H2N9) (GenBank: CY064950.1) |
| <b>Antibiotic Resistance</b><br>Ampicillin (encoded by <i>bla</i> gene)                     | <i>bla</i> sequence present                                                          | <i>bla</i> sequence present                                                         |
| <b>Concentration by Qubit® Measurement</b>                                                  | ≥ 2 µg/mL                                                                            | 3.4 µg in 100 µL/vial (34 µg/mL)                                                    |
| <b>Amount per Vial</b>                                                                      | Report results                                                                       | 3.4 µg/vial                                                                         |
| <b>OD<sub>260</sub>/OD<sub>280</sub> Ratio (pre vial)</b>                                   | 1.7 to 2.1                                                                           | 1.98                                                                                |
| <b>Effective Bacterial Transformation</b><br>Invitrogen™ <i>Escherichia coli</i> Stbl2™     | ≥ 50 colonies/ng                                                                     | 64 colonies/ng                                                                      |

<sup>1</sup>The sequence was assembled pre-vial using *de novo* analysis. The complete plasmid sequence is provided on the BEI Resources webpage.

/Sonia Bjorum Brower/

Sonia Bjorum Brower

18 APR 2024

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

